Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness

Abstract

BackgroundNew digital technologies offer providers the promise of more accurately tracking patients’ medication adherence. It is unclear, however, whether access to such information will affect provider treatment decisions in the real world.MethodsUsing prescriber-reported information on patient non-compliance from health insurance claims data between 2008 and 2014, we examined whether prescribers’ knowledge of non-compliance was associated with different prescribing patterns for patients with serious mental illness (SMI). We examined patients who initiated an oral atypical antipsychotic, but were later objectively non-adherent to this treatment, defined as proportion of days covered (PDC) <0.8. We examined how a physician’s awareness of patient non-compliance (ICD-9 diagnosis code: V15.81) was correlated with the physician’s real-world treatment decisions for that patient. Treatment decisions studied included the share of patients who increased antipsychotic dose, augmented treatment, switched their antipsychotic, or used a long-acting injectable (LAI).ResultsAmong the 286,249 patients with SMI who initiated an antipsychotic and had PDC <0.8, 4,033 (1.4%) had documented non-compliance. When prescribers documented non-compliance, patients were more likely to be switched to another antipsychotic (32.8% vs 24.7%, P<0.001), have their dose increased (24.4% vs 22.1%, P=0.004), or receive an LAI (0.09% vs 0.04%, P=0.008), but were less likely to have augmented therapy with another antipsychotic (1.1% vs 1.3%, P=0.035) than patients without documented non-compliance.ConclusionAmong SMI patients with documented non-compliance, the frequency of dose, medication switches, and LAI use were higher and augmentation was lower compared to patients without documented non-compliance. Access to adherence information may help prescribers more rapidly switch ineffective medications as well as avoid unnecessary medication augmentation.

Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain

“… 3 Lack of adherence contributes to an inadequate response or failure to treatment, worsening or disease relapse, and unnecessary treatment changes. 4 It has been stated that compliance declines over time. 5 This is important because a lack of adherence to pharmacologic therapy is a prevalent issue in the treatment of chronic diseases such as RA.…”

Impact of treatment-related discussions on healthcare resource use and costs among patients with severe mental illness

“…Until providers have greater access to reliable medication use (i.e. treatment adherence/compliance) data including individual reasons for non-compliance 20,31 , the impact of compliance-related discussions occurring after an acute event may not be fully understood. Nevertheless, evidence from this study suggests that early discussions about compliance are associated with a more consistent ongoing relationship between patient and provider and lower risk for a subsequent acute event.…”

“…In clinical practice, provider insight into patient compliance with the treatment regimen influences treatment decisions. A full understanding of patient compliance with pharmacotherapy may prevent unnecessary therapy augmentations or allow ineffective medications to be switched more quickly 20,21 .…”

Medication adherence in patients with psychiatric disorders in Tehran

“…This highlights the paramount role of both pharmacists and physicians in helping patients better adapt themselves to the treatment by informing them of the side effects of drugs and strategies to deal with them. For instance, researchers have empirically manifested the strategic role of pharmacists and physicians in increasing patients' adherence to medications . More specifically, a recent study conducted on physicians who were specialized in treating patients with psychiatric disorders showed if prescribers were provided with information on non‐adherence, they would effectively manage pharmacotherapy …”